TOPLINE

A recent meta-analysis of randomised trials found no clear superiority or inferiority of ceftaroline and ceftobiprole monotherapy over standard-of-care therapies for clinical cure in patients with non-urinary Staphylococcus aureus infections.

METHODOLOGY

• Researchers conducted a meta-analysis comparing ceftaroline and ceftobiprole monotherapy with standard-of-care therapies for clinical cure in patients with non-urinary S aureus infections.
• A total of 16 studies focusing on S aureus infections at any body site except the urinary tract in adults were included, of which 11 evaluated ceftaroline (n = 1030) and five evaluated ceftobiprole (n = 1265).
• The primary outcome was clinical cure — defined as the resolution of all signs and symptoms of infection or clinical improvement assessed at 7 or 14 days after the end of therapy — consistently reported across S aureus trial subgroups.

TAKEAWAY

• Odds of clinical cure were not significantly higher for ceftaroline (pooled odds ratio [OR], 1.38; 95% credible interval [CrI], 0.81-2.44) and ceftobiprole (pooled OR, 0.99; 95% CrI, 0.59-1.62) than for standard-of-care therapies.
• Clinical cure for the methicillin-resistant S aureus subgroup was also non-significant.
• Similarly, overall adverse events for ceftaroline and ceftobiprole showed an OR of 0.94 and 1.13, respectively, both being non-significantly different from the standard-of-care therapies.

IN PRACTICE

"From a policy standpoint, our analysis underscores the importance of generating syndrome specific evidence before widespread adoption of newer, often more costly agents," the authors wrote.

SOURCE

The study was led by Emanuele Rando, Università Cattolica del Sacro Cuore, Rome, Italy. It was published onlineon July 14, 2026, in the Journal of Antimicrobial Chemotherapy.

LIMITATIONS

The number of randomised trials was small, with several subgroup analyses including only two to four studies. The overall pooled analyses combined clinically distinct infection syndromes varying by baseline prognosis, outcome relevance, and comparator regimens. Clinical cure was assessed at 7-14 days after the end of therapy, which may not have adequately captured treatment benefits for invasive S aureus infections.

DISCLOSURES

This study was conducted as part of the authors' routine work, and the authors reported having no conflicts of interest.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.